Its interesting. Sintx is treated like its a biopharm company the way its heavily shorted. Biopharms have a great deal of risk so its understandable. However Sintx tech has 10 years on market being implanted (6yrs at IPO). Why sintx is treated like its as risky I do not know. However I suspect it's just the result of having to use questionable funds to fund R&D. This sets up major opportunities for value based investing.
News 
Market Data 
Discover 
